More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
|Articles|December 30, 2013
Segment 1 - Introduction to NSCLC
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).
Advertisement
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC). This includes the therapeutic importance of distinguishing NSCLC by histology. Dr Sugarbaker says that adenocarcinoma, squamous cell carcinoma (SCC), and large-cell carcinoma (LCC) are all considered in the broader category of NSCLC. The therapy for each of these histologies is determined by different indicators, and then classified into stages I-IV.
Advertisement
Related to this article
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Experts Weigh Flu Vaccine Timing in Pregnancy and Pediatric Uptake
5